- Home
- SPHL vs ENLV Comparison
SPHL vs ENLV Comparison
Compare SPHL & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- ENLV
- Stock Information
- Founded
- SPHL 2002
- ENLV 2005
- Country
- SPHL Singapore
- ENLV Israel
- Employees
- SPHL N/A
- ENLV N/A
- Industry
- SPHL Homebuilding
- ENLV Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- ENLV Health Care
- Exchange
- SPHL Nasdaq
- ENLV Nasdaq
- Market Cap
- SPHL 27.5M
- ENLV 24.4M
- IPO Year
- SPHL 2024
- ENLV 1995
- Fundamental
- Price
- SPHL $2.60
- ENLV $1.00
- Analyst Decision
- SPHL
- ENLV Strong Buy
- Analyst Count
- SPHL 0
- ENLV 2
- Target Price
- SPHL N/A
- ENLV $9.50
- AVG Volume (30 Days)
- SPHL 410.6K
- ENLV 51.0K
- Earning Date
- SPHL 02-21-2025
- ENLV 03-28-2025
- Dividend Yield
- SPHL N/A
- ENLV N/A
- EPS Growth
- SPHL 413.11
- ENLV N/A
- EPS
- SPHL 0.09
- ENLV N/A
- Revenue
- SPHL $11,020,429.00
- ENLV N/A
- Revenue This Year
- SPHL N/A
- ENLV N/A
- Revenue Next Year
- SPHL N/A
- ENLV N/A
- P/E Ratio
- SPHL $30.41
- ENLV N/A
- Revenue Growth
- SPHL 112.84
- ENLV N/A
- 52 Week Low
- SPHL $1.42
- ENLV $0.81
- 52 Week High
- SPHL $7.16
- ENLV $4.59
- Technical
- Relative Strength Index (RSI)
- SPHL N/A
- ENLV 32.92
- Support Level
- SPHL N/A
- ENLV $1.00
- Resistance Level
- SPHL N/A
- ENLV $1.09
- Average True Range (ATR)
- SPHL 0.00
- ENLV 0.08
- MACD
- SPHL 0.00
- ENLV -0.00
- Stochastic Oscillator
- SPHL 0.00
- ENLV 12.50
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.